According to Fortune Business Insights, the global veterinary drugs market size was valued at USD 30.54 billion in 2025. The market is projected to grow from USD 32.20 billion in 2026 to USD 53.05 billion by 2034, exhibiting a CAGR of 6.44% during the forecast period.
The veterinary drugs market is experiencing steady expansion as livestock owners, veterinary professionals, pet owners, and animal healthcare organizations increasingly focus on disease prevention, treatment, and overall animal health. Rising pet ownership, growing expenditure on companion animal healthcare, increasing awareness regarding zoonotic diseases, and the need to maintain livestock productivity are contributing to demand for veterinary drugs. The veterinary drugs market includes medicines and therapeutic products used to prevent and treat infections, parasitic diseases, metabolic disorders, and other health conditions affecting companion animals and livestock. Increasing investments in animal healthcare infrastructure and improvements in veterinary diagnostics are also supporting market development. In 2026, the veterinary drugs market is expected to benefit from the increasing adoption of preventive healthcare approaches and the growing emphasis on maintaining animal welfare and food safety.
Continue reading for more details:
https://www.fortunebusinessinsights.com/industry-reports/veterinary-drugs-market-100171
Market Segmentation
The veterinary drugs market can be segmented based on product, animal type, route of administration, distribution channel, and geography. Based on product, the market is categorized into pharmaceuticals, biologics, and medicated feed additives. Pharmaceuticals represent an important portion of the veterinary drugs market because of their extensive application in treating bacterial, viral, parasitic, and other animal diseases. Biologics, including vaccines and other biological products, are also gaining importance as preventive healthcare becomes increasingly prominent. Based on animal type, the veterinary drugs market is divided into companion animals and livestock animals. Companion animals, including dogs and cats, are witnessing increasing demand for medicines because pet owners are spending more on preventive and therapeutic healthcare. Livestock animals such as cattle, pigs, poultry, and other farm animals also account for significant demand because disease prevention and treatment are essential for maintaining productivity and reducing economic losses. By route of administration, the veterinary drugs market includes oral, parenteral, and topical categories. Oral administration is widely used because of convenience, while injectable and topical treatments are selected according to the specific medical condition and animal type. Based on distribution channel, the market is segmented into veterinary hospitals and clinics, pharmacies and drug stores, online channels, and other channels. Veterinary hospitals and clinics remain important distribution points due to professional diagnosis and prescription requirements.
Key Players
- Zoetis Inc.
- Merck & Co., Inc.
- Elanco Animal Health Incorporated
- Boehringer Ingelheim International GmbH
- Virbac
- Ceva Santé Animale
- Vetoquinol
- Dechra Pharmaceuticals Limited
- IDEXX Laboratories, Inc.
- Indian Immunologicals Limited
Market Growth
The veterinary drugs market is projected to demonstrate consistent growth between 2026 and 2034. The market is expected to increase from USD 32.20 billion in 2026 to USD 53.05 billion by 2034, reflecting a CAGR of 6.44%. One of the major factors supporting veterinary drugs market growth is the rising prevalence of animal diseases. Livestock and companion animals are vulnerable to infectious, parasitic, and chronic diseases, increasing the need for effective therapeutic and preventive medicines. Growing pet ownership is another important contributor to veterinary drugs market expansion. Pets are increasingly considered family members, encouraging owners to spend more on vaccinations, treatments, parasite control, and long-term disease management. The growing livestock population and rising demand for animal-derived food products are also generating demand for veterinary drugs. Farmers and livestock producers increasingly rely on veterinary healthcare products to maintain animal health, improve productivity, and minimize losses caused by disease outbreaks. Additionally, increasing awareness regarding zoonotic diseases is encouraging governments, veterinary organizations, and animal owners to adopt preventive healthcare measures. Technological advancements in veterinary medicine are further contributing to the development of innovative products with improved efficacy and safety profiles. Pharmaceutical companies are increasing investments in research and development to introduce new treatments for complex animal health conditions. In 2026, continued innovation in vaccines, antiparasitic products, antibiotics, and other therapeutic categories is expected to strengthen the veterinary drugs market. Regulatory initiatives focused on responsible use of veterinary medicines and antimicrobial stewardship are also influencing product development and market strategies.
Restraining Factors
Despite favorable growth prospects, several factors may restrain the veterinary drugs market. Stringent regulatory requirements for the approval, manufacturing, distribution, and use of veterinary medicines can increase development costs and extend product commercialization timelines. Regulatory authorities are placing greater emphasis on drug safety, efficacy, residue control, and responsible antimicrobial use, requiring manufacturers to maintain rigorous compliance procedures. The growing concern regarding antimicrobial resistance is another challenge for the veterinary drugs market. Excessive or inappropriate use of antibiotics in animals can contribute to antimicrobial resistance, leading to tighter regulations and greater scrutiny of antibiotic products. This may affect the sales potential of certain veterinary pharmaceuticals while encouraging manufacturers to develop alternative treatments and preventive solutions. High treatment costs can also limit access to veterinary healthcare, particularly in developing and price-sensitive markets. Small livestock farmers and pet owners with limited disposable income may postpone or avoid professional veterinary treatment because of medication and consultation expenses. Furthermore, limited availability of veterinary healthcare professionals and inadequate animal healthcare infrastructure in certain emerging economies can restrict market penetration. Counterfeit and low-quality veterinary medicines may also create challenges by affecting consumer confidence and posing risks to animal health. These factors may moderate the pace of veterinary drugs market growth despite rising demand.
Regional Analysis
North America dominated the veterinary drugs market with a market share of 38.57% in 2025. The region's leading position is supported by high pet ownership, substantial spending on animal healthcare, advanced veterinary infrastructure, and the presence of major animal health companies. The U.S. represents a significant contributor to the regional veterinary drugs market because of strong demand for companion animal medicines and extensive livestock healthcare requirements. The region is also characterized by increasing adoption of preventive veterinary care, advanced diagnostic technologies, and innovative therapeutic products. Europe is another important region in the veterinary drugs market, supported by established veterinary healthcare systems, increasing awareness of animal welfare, and significant expenditure on companion and livestock animal healthcare. Regulatory emphasis on animal health and food safety also supports demand for high-quality veterinary medicines. Asia Pacific is expected to witness significant opportunities during the forecast period because of the expanding livestock population, rising pet ownership, improving veterinary infrastructure, and increasing awareness of animal diseases. Countries such as China, India, Japan, and other Asian economies are investing in animal healthcare capabilities, creating opportunities for pharmaceutical and biologics manufacturers. In emerging economies, the increasing importance of livestock production is encouraging farmers to adopt veterinary medicines to improve animal health and productivity. Latin America is supported by its large livestock sector and demand for animal-derived food products. Increasing focus on disease prevention and livestock productivity is expected to support the regional veterinary drugs market. The Middle East & Africa region is also expected to experience gradual development as governments and organizations increase efforts to improve veterinary healthcare infrastructure, disease management, and livestock health. Overall, regional growth in the veterinary drugs market will be influenced by animal population, healthcare expenditure, disease prevalence, regulatory conditions, and access to veterinary services.
What’s Driving Japan’s Market? Discover the Latest -Veterinary Drugs Market - Insights-